



Study on Drug—Bee Venom Interactions

Guest Editor:

Dr. Woojin Kim

Department of Physiology,
College of Korean Medicine,
Kyung Hee University, Seoul
02453, Republic of Korea

Deadline for manuscript
submissions:

closed (31 January 2022)

Message from the Guest Editor

The therapeutic effects of bee venom and its subcomponents, such as melittin and phospholipase A2, are relatively well known. To list a few examples, neuropathic pain, progressive muscle atrophy, idiopathic Parkinson's disease, and cancers were all shown to be attenuated by bee venom administration. Furthermore, their mechanisms of action are also beginning to be clarified. However, in order for bee venom to be widely used against different types of diseases, its interaction with conventionally used drugs must be understood; thus far, the effects of their interactions have been poorly investigated.

Thus, this Special Issue of *Toxins* is devoted to understanding the interactions of bee venom and its subcomponents (i.e., apamin, melittin, phospholipase A2, etc.) with other drugs used to treat various diseases. We welcome all research focused on the combination effect of bee venom and other conventionally used drugs (i.e., anti-analgesic, anti-inflammatory, anti-cancerogenic drugs). Bee venom and drugs could be treated simultaneously or sequentially. In vivo and in vitro studies are all welcomed.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Jay Fox

Department of Microbiology,
University of Virginia,
Charlottesville, VA, USA

Message from the Editor-in-Chief

Toxinology is an incredibly diverse area of study, ranging from field surveys of environmental toxins to the study of toxin action at the molecular level. The editorial board and staff of *Toxins* are dedicated to providing a timely, peer-reviewed outlet for exciting, innovative primary research articles and concise, informative reviews from investigators in the myriad of disciplines contributing to our knowledge on toxins. We are committed to meeting the needs of the toxin research community by offering useful and timely reviews of all manuscripts submitted. Please consider *Toxins* when submitting your work for publication.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, AGRIS, and other databases.**

Journal Rank: JCR - Q1 (Toxicology) / CiteScore - Q1 (Toxicology)

Contact Us

Toxins Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/toxins
toxins@mdpi.com
[X@Toxins_Mdpi](#)